Core Laboratories N.V.
NYSE:CLBOil & Gas Equipment & Services
+$0.12 today
- Market cap
- $387.21M
- Beta
- 0.99
- P/E (TTM)
- 18.3
- EPS (TTM)
- $0.63
- Dividend yield
- 0.35%
Volume 0.52M
Average 0.49M
CLB Pre-Tax Margin
Income before tax as a percentage of revenue.
Core Laboratories N.V.NYSE: CLB
Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026
Pre-tax margin narrows to -0.8%
Pre-tax margin was -0.8% in Q1 FY2026, down 2.3 pp from a year earlier. On a trailing-twelve-month basis it was 8.2%, down 0.1 pp year over year. Over 3 fiscal years it widened by 2.6 pp.
Context
- Pre-tax margin widened in 2 of the last 3 fiscal years.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 8.7%
- Year-over-year change
- -0.1pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.7% | -0.1pp |
| FY2024 | 2024-12-31 | 8.8% | +0.7pp |
| FY2023 | 2023-12-31 | 8.1% | +2.0pp |
| FY2022 | 2022-12-31 | 6.1% | -1.6pp |
| FY2021 | 2021-12-31 | 7.7% | — |
Pre-Tax Margin vs competitors
How CLB compares with its peers on the latest reported figures
- CLB's LTM Mar 2026 pre-tax margin of 8.2% is the 2nd highest of the 10 companies compared; the peer median is -7.0%.
- Its year-over-year change of -0.1 pp is the 3rd highest of 9, against a peer median of -9.8 pp.
- Over three fiscal years its change of +2.6 pp compares with a peer median of -1.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 15.1% | +13.9 pp | +26.1 pp | |
| LTM Mar 2026 | 8.2% | -0.1 pp | +2.6 pp | |
| LTM Mar 2026 | 6.9% | -3.5 pp | +70.2 pp | |
| LTM Mar 2026 | 2.0% | +1.2 pp | +0.1 pp | |
| LTM Mar 2026 | 1.8% | -6.4 pp | +3.9 pp | |
| LTM Mar 2026 | -7.0% | -20.8 pp | -29.4 pp | |
| LTM Mar 2026 | -9.1% | -13.1 pp | -48.2 pp | |
| LTM Mar 2026 | -22.7% | -38.9 pp | -38.3 pp | |
| LTM Mar 2026 | -27.7% | -32.9 pp | -2.1 pp | |
| LTM Mar 2026 | -39091.7% | — | — | |
| Peer median (excluding CLB) | -7.0% | -9.8 pp | -1.0 pp | |
Competitors are the stored peer set for CLB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 470.25M | 489.74M | 509.79M | 523.85M | 526.52M |
| Cost of Revenue | 386.41M | 410.82M | 415.74M | 435.48M | 432.24M |
| Gross Profit | 83.84M | 78.92M | 94.05M | 88.37M | 94.28M |
| Gross Margin | 17.8% | 16.1% | 18.4% | 16.9% | 17.9% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 44.17M | 38.12M | 38.89M | 38.59M | 44.23M |
| Operating Expenses | 38.58M | 37.4M | 39.41M | 29.82M | 43.8M |
| Depreciation & Amortization | 18.52M | 17.16M | 15.78M | 14.95M | 14.65M |
| EBITDA | 63.78M | 58.69M | 70.42M | 73.51M | 71.12M |
| EBITDA Margin | 13.6% | 12.0% | 13.8% | 14.0% | 13.5% |
| Operating Income | 45.26M | 41.52M | 54.64M | 58.56M | 50.49M |
| Operating Margin | 9.6% | 8.5% | 10.7% | 11.2% | 9.6% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 9.15M | 11.57M | 13.43M | 12.37M | 10.57M |
| Other Income / Expenses | (9.15M) | (11.57M) | (13.43M) | (12.37M) | (4.59M) |
| Income Before Tax | 36.11M | 29.95M | 41.21M | 46.19M | 45.9M |
| Pre-Tax Margin | 7.7% | 6.1% | 8.1% | 8.8% | 8.7% |
| Income Tax Expense | 15.89M | 10.3M | 4.19M | 14.03M | 15.51M |
| Net Income | 19.73M | 19.45M | 36.68M | 31.4M | 29.67M |
| Net Margin | 4.2% | 4.0% | 7.2% | 6.0% | 5.6% |
| EPS (Basic) | 0.43 | 0.42 | 0.79 | 0.67 | 0.68 |
| EPS (Diluted) | 0.42 | 0.42 | 0.77 | 0.66 | 0.68 |
| Weighted Avg Shares | 46.01M | 46.33M | 46.68M | 46.9M | 46.5M |
| Weighted Avg Shares (Diluted) | 46.69M | 46.81M | 47.52M | 47.69M | 46.5M |
Core Laboratories N.V.
NYSE:CLB
Intrinsic Alpha fair value
Locked
Current Price
$8.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.